Basic Information
Erivedge
Regulatory Information
EMEA/H/C/002602
July 12, 2013
April 25, 2013
15
March 20, 2023
Company Information
Germany
Emil-Barell-Strasse 1 79639 Grenzach-Wyhlen
Roche Registration GmbH
Active Substances Detail
EMA Resources
Detailed Information
Therapeutic Indication
### Therapeutic indication Erivedge is indicated for the treatment of adult patients with: \- symptomatic metastatic basal cell carcinoma \- locally advanced basal cell carcinoma inappropriate for surgery or radiotherapy
Overview Summary
This is a summary of the European public assessment report (EPAR) for Erivedge. It explains how the Agency assessed the medicine to recommend its authorisation in the European Union (EU) and its conditions of use. It is not intended to provide practical advice on how to use Erivedge. For practical information about using Erivedge, patients should read the package leaflet or contact their doctor or pharmacist.